Cytokine modulated cell-membrane bound tumour necrosis factor expression is associated with enhanced monocyte-mediated killing of human leukaemic targets

Leukemia Research

Volumn 24, Issue 4, 2000, Pages 317-330

  Williams, Marc A ^a   Newland, Adrian C ^a   Kelsey, Stephen M ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

GM CSF; IL 3; Immunosurveillance; Immunotherapy; Leukemia; Minimal residual disease; Monocyte mediated cytotoxicity; Tumor necrosis factor

Indexed keywords

CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; LIPOPOLYSACCHARIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 3; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL KILLING; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOMODULATION; IMMUNOSURVEILLANCE; LEUKEMIA CELL; MINIMAL RESIDUAL DISEASE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CYTOTOXICITY, IMMUNOLOGIC; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-3; L-LACTATE DEHYDROGENASE; LEUKEMIA; MONOCYTES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034000118     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00189-7     Document Type: Article

References (68)

1. Fischer D.G., Hubbard W.J., Koren H.S. Tumour cell killing by freshly isolated peripheral blood monocytes. Cell. Immunol. 58:1981;426-435.
2. Philip R., Epstein L.B. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, interferon-γ and interleukin-1. Nature. 323:1986;86-89.
3. Woods K.M., Chapes S.K. Three distinct cell phenotypes of induced TNF cytotoxicity and their relationship to apoptosis. J. Leuk. Biol. 53:1993;37-44.
4. Kriegler M., Perez C., Defay K., Albert I., Lu S.D. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 53:1988;45-53.
5. Perez C., Albert I., Defay K., Zachariades N., Gooding L., Kriegler M. A non-secretable cell-surface mutant of tumour necrosis factor (TNF) kills by cell-to-cell contact. Cell. 63:1990;251-260.
6. Luttig B., Decker T., Lohmann-Matthes H. Evidence for the existence of two forms of membrane tumor necrosis factor: an integral membrane protein and a molecule attached to its receptor. J. Immunol. 143:1989;4034-4038.
7. Wiegmann K., Scutze S., Kampen E., Himmler A., Machleidt T., Kronke M. Human 55 kDa receptor for tumor necrosis factor coupled to signal transduction cascades. J. Biol. Chem. 267:1992;17997-18001.
8. Brakebusch C., Nophar Y., Kemper O., Engelmann H., Wallach D. Cytoplasmic truncation of the p55 tumor necrosis factor (TNF) receptor abolishes signalling but not induced shedding of the receptor. EMBO J. 11:1992;943-950.
9. Engelmann H., Holtmann H., Brakebusch C., Avni Y., Sarov I., Nophar Y., Hadas E., Leitner O. Antibodies to a soluble form of a tumor necrosis factor receptor have TNF-like activity. J. Biol. Chem. 265:1992;14497-14504.
10. Higuchi M., Aggerwal B.B. Differential roles of the TNF receptor in TNF-induced cytotoxicity, DNA fragmentation and differentiation. J. Immunol. 152:1994;4017-4025.
11. Peck R., Brockhaus M., Frey J.R. The principal tumor necrosis factor receptor in monocyte cytotoxicity is on the effector cell, not on the target cell. Cell. Immunol. 132:1991;308-318.
12. Heller R.A., Song K., Fan N., Chang D.J. The p70 tumor necrosis factor receptor mediates cytotoxicity. Cell. 70:1992;47-56.
13. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilisation of the bioactivity of tumor necrosis factor by its soluble receptors. J. Exp. Med. 175:1992;323-329.
14. Engelmann H., Aderka D., Rubinstein M., Rotman D., Wallach D. A tumor necrosis factor binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J. Biol. Chem. 264:1989;11974-11980.
15. Olsson I., Gatanga T., Gullberg U., Lantz M., Granger G.A. Tumor necrosis factor (TNF) binding proteins (TNF receptor forms) with possible roles in inflammation and malignancy [Review]. Eur. Cytokine Network. 4:1993;169-180.
16. Metcalf D. The molecular biology and function of the granulocyte-macrophage colony-stimulating factors. Blood. 67:1986;257-267.
17. Nicola N.A. Hematopoietic cell growth factors and their receptors. Annu. Rev. Biochem. 58:1989;45-77.
18. Isfort R.J., Ihle J.N. Multiple haemopoietic growth factors signal through tyrosine phosphorylation. Growth Factors. 2:1990;213-220.
19. Kanakura Y., Druker B., Cannistra S.A., Furukawa Y., Torimoto Y., Griffin J.D. Signal transduction of the granulocyte-macrophage colony stimulating factor and IL-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins. Blood. 76:1990;706-715.
20. Kitamura T., Sato N., Arai K., Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared β subunit for the human IL-3 and GM-CSF receptors. Cell. 66:1991;1165-1174.
21. Paquette R.L., Zhou J.Y., Yang Y.C., Clark S.C., Koeffler H.P. Recombinant gibbon interleukin-3 acts synergistically with recombinant human G-CSF and GM-CSF in vitro. Blood. 71:1988;1596-1600.
22. Yuo A., Kitegawa S., Motoyoshi K., Azuma E., Saito M., Takaku F. Rapid priming of human monocytes by human haemopoietic growth factors: granulocyte-macrophage colony stimulating factor (CSF), macrophage-CSF and interleukin-3 selectively enhance superoxide release triggered by receptor-mediated agonists. Blood. 79:1992;1553-1557.
23. Fabian I., Shapira E., Gadish M., Kletter Y., Nagler A., Flidel O., Slavin S. Effects of Interleukin-3, macrophage and granulocyte-macrophage colony stimulating factor on monocyte function following autologous bone marrow transplantation. Leuk. Res. 16:1992;703-709.
24. Cannistra S.A., Vallenga E., Groshek P., Rambaldi A., Griffin J.D. Human granulocyte-macrophage colony stimulating factor and interleukin-3 stimulate monocyte cytotoxicity through a TNF-dependent mechanism. Blood. 71:1988;672-676.
25. Grabstein KH, Urdal DL, Tushinski R, Mochizuki, Price V, Cantrell MA, Gillis S, Conlon PJ, 1986. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor: Science; 232:506-8.
26. Williams M.A., Kelsey S.M., Collins P.W., Gutteridge C.N., Newland A.C. Administration of recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF) activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high-dose chemotherapy. Br. J. Haematol. 90:1995;31-40.
27. Williams M.A., Kouromoussis I., Syndercombe-Court D., Hendry L., Newland A.C., Kelsey S.M. Administration of recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy regulates the expression and secretion of monocyte tumor necrosis factor (TNF) and TNF receptors p55 and p75. Blood. 86:1995;4234-4242.
28. Williams M.A., Newland A.C., Kelsey S.M. Monocyte-mediated killing of human leukaemia is enhanced by administration of granulocyte-macrophage colony stimulating factor following chemotherapy. Br. J. Haematol. 98:1997;960-968.
29. Williams M.A., White S.A., Miller J.J., Toner C., Withington S., Newland A.C., Kelsey S.M. Granulocyte-macrophage colony stimulating factor induces activation and restores respiratory burst activity in monocytes from septic patients. J. Infect. Dis. 177:1998;107-115.
30. Williams M.A., Withington S., Newland A.C., Kelsey S.M. Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulocyte-macrophage colony-stimulating factor ex vivo. J. Infect. Dis. 178:1998;1421-1433.
31. Rosner G. Fundamentals of Biostatistics (edition 3). Boston MA, PWS-Kent, 1999.
32. Holtmann H., Hahn T., Wallach D. Interrelated effects of tumor necrosis factor and interleukin 1 on cell viability. Immunobiology. 177:1988;7-22.
33. Peck R., Brockhaus M., Frey J.R. Cell surface tumour necrosis factor (TNF) accounts for monocyte and lymphocyte-mediated killng of TNF-resistant target cells. Cell. Immunol. 122:1989;1-10.
34. van de Loosedrecht A.A., Beelan R.H.B., Ossenkopple G.J., Broekhoven M.G., Langenhuijsen M.M.A.C. Cellular and cytokine dependent monocyte-mediated leukemic cell death:modulation by interferon gamma and TNF. Exp. Hematol. 21:1993;461-468.
35. Hasday J.F., Shah E.M., Liebermann A.P. Macrophage tumor necrosis factor release is induced by contact with some tumors. J. Immunol. 145:1990;371-379.
36. Yamauchi T., Sagawa T., Kanoh M., Utsami S. Lymphokine-independent, leukemia cell-mediated induction of tumor necrosis factor in human monocytes. Cancer Res. 50:1990;2708-2712.
37. Buckle A.M., Joyarum K., Hogg N. Colony stimulating factors and interferon gamma differentially affect cell surface molecules shared by monocytes and neutrophils. Clin. Exp. Immunol. 81:1990;339-344.
38. Roilides E., Blake C., Holmes A., Pizzo P.A., Walsh T.J. Granulocyte-macrophage colony-stimulating factor and interferon-gamma prevent dexamethasone-induced immunosuppression of antifungal monocyte activity against Aspergillus fumigatus hyphae. J. Med. Vet. Mycol. 34:1996;63-69.
39. Takahashi GW, Andrews GF 3rd, Lilly MB, Singer JW, Alderson MR. Effect of granulocyte-macrophage colony-stimulating factor and interleukin-3 on interleukin-8 production by human neutrophils and monocytes. Blood 1993;81:357-64.
40. Khwaja A., Addison I.E., Johnson B., Yong K., Linch D.C. Interleukin-3 administration enhances human monocyte function in vivo. Br. J. Haematol. 88:1994;515-519.
41. Oster W., Lindemann A., Mertelsmann R., Hermann F. GM-CSF and multilineage CSF recruit human monocytes to express granulocyte CSF. Blood. 73:1989;64-67.
42. Maurer A.B., Ganser A., Buhl R., Seipelt G., Ottmann O.G., Mentzel U., Geissler R.G., Hoelzer D. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia. 7:1993;1728-1733.
43. Wiltschke C., Krainer M., Wagner A., Linkesch W., Zielinski C.C. Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. Exp. Hematol. 23:1995;402-406.
44. Cannistra S.A., Rambaldi A., Spriggs D.R., Hermann F., Kufe D., Griffin J.D. Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell-line and by normal human monocytes. J. Clin. Invest. 79:1987;1720-1728.
45. Sisson S.D., Dinarello C.A. Production of interleukin-1α, interleukin-1β and tumor necrosis factor by human mononuclear cells stimulated with granulocyte-macrophage colony-stimulating factor. Blood. 72:1988;1368-1374.
46. Kohn F.R., Philips G.L., Lingemann H.G. Regulation of tumor necrosis factor alpha production and gene expression in monocytes. Bone Marrow Transplant. 9:1992;369-376.
47. Rhoades K.L., Cai S., Golub S.H., Economou J.S. Granulocyte-macrophage colony-stimulating factor and interleukin-4 differentially regulate the human tumor necrosis factor-alpha promoter region. Cell. Immunol. 161:1995;125-131.
48. Fidler I.J., Schroit A.J. Recognition and destruction of neoplastic cells by activated macrophages: discrimination of altered self. Biochim. Biophys. Acta. 948:1988;151-159.
49. Munn D.H., Cheung N.K.V. Phagocytosis of tumor cells by human macrophages cultured in recombinant human macrophage colony stimulating factor. J. Exp. Med. 172:1990;231-237.
50. Green S.J., Chen T.Y., Crawford R.M., Nacy C.A., Morrison D.C., Meltzer M.S. Cytotoxic activity and production of toxic nitrogen oxides by macrophages treated with IFN-α and monoclonal antibodies against the 73-kDa lipopolysaccahride receptor. J. Immunol. 149:1992;2069-2075.
51. Zarling J.M., Shoyab M., Marquardt H., Hansom M.B., Lioubin M.N., Todaro G.J. Oncostatin-M: a growth regulator produced by differentiated histiocytic lymphoma cells. Proceed. Nat. Acad. Sci. USA. 83:1986;9739-9743.
52. Grell M., Becke F.M., Wajant H., Mannel D.N., Scheurich P. TNF receptor type 2 mediates thymocyte proliferation independently of TNF receptor type 1. Eur. J. Immunol. 28:1998;257-263.
53. Wong G.W.H., Tartaglia L.A., Lee M.S., Goeddel D.V. Antiviral activity of tumor necrosis factor (TNF) is signalled through the 55-kDa type I TNF receptor. J. Immunol. 149:1992;3350-3353.
54. Fahlman C., Jacobsen F.W., Veiby O.P., McNiece I.K., Blomhoff H.K., Jacobsen S.E. Tumor necrosis factor-alpha (TNF-alpha) potently enhances in vitro macrophage production from primitive murine haemopoietic progenitor cells in combination with stem cell factor and interleukin-7: novel stimulatory role of p55 TNF receptors. Blood. 84:1994;1528-1533.
55. Nashleanas M., Kanaly S., Scott P. Control of Leishmania major infection in mice lacking TNF receptors. J. Immunol. 160:1998;5506-5513.
56. Salkowski C.A., Detore G., McNally R., van Rooijen N., Vogel S.N. Regulation of inducible nitric oxide synthase messenger RNA expression and nitric oxide production by lipopolysaccharide in vivo: the roles of macrophages, endogenous IFN-gamma, and TNF receptor-1-mediated signaling. J. Immunol. 158:1997;905-912.
57. Takakuwa T., Knopf H.P., Sing A., Carsetti R., Galanos C., Freudenberg M.A. Induction of CD14 expression in LPSn, LPSd and tumor necrosis factor receptor-deficient mice. Eur. J. Immunol. 26:1996;2686-2692.
58. Kitagawa S., Yuo A., Yagisawa M., Azuma E., Yoshida M., Furukawa Y., Takahashi M., Masuyama J., Takaku F. Activation of human monocyte function by tumor necrosis factor: rapid priming for enhanced release of superoxide and erythrophagocytosis, but no direct triggering of superoxide release. Exp. Hematol. 24:1996;559-567.
59. van der Poll T., Calvano S.E., Kumar A., Braxton C.C., Coyle S.M., Barbosa K., Moldawer L.L., Lowry S.F. Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood. 86:1995;2754-2759.
60. Williams M.A., Kelsey S.M., Newland A.C. GM-CSF and stimulation of monocyte/macrophage function. In vivo relevance and in vitro observations. Eur. J. Cancer. 35(3):1999;S18-S23. (Suppl.).
61. Wiltchke C., Krainer M., Wagner A., Linkesch W., Zielinski C.C. Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. Exp. Hematol. 23:1995;402-406.
62. Wing E.J., Magee M., Whiteside T., Kaplan S., Shadduck R. Recombinant human granulocyte-macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of TNF and interferon in cancer patients. Blood. 73:1989;643-646.
63. Chachoua A., Oratz R., Hoogmoed R., Caron D., Peace D., Liebes L., Blum R.H., Vilcek J. Monocyte activation following systemic administration of human granulocyte-macrophage colony-stimulating factor. J. Immunother. Emphasis Tumor Immunol. 16:1994;132-141.
64. Faradji A., Bohbot A., Schmitt-Goguel M., Siffert J.C., Dumont S., Wiesel M.L., Piemont Y., Eischen A., Bergerat J.P., Bartholeyns J. Large scale isolation of human blood monocytes by continuous flow centrifugation leukapheresis and counterflow elutriation for adoptive cellular immunotherapy in cancer patients. J. Immunol. Methods. 174:1994;297-309.
65. Stevenson H.C., Keenan A.M., Woodhouse C., Ottow R.T., Miller P., Steller E.P., Foon K.A., Abrams P.G., Beman J., Larson S.M. Fate of gamma-interferon-activated killer blood monocytes adoptively transferred into the abdominal cavity of patients with peritoneal carcinomatosis. Cancer Res. 47:1987;6100-6103.
66. Boccoli G., Masciulli R., Ruggeri E.M., Carlini P., Giannella G., Montesoro E., Mastroberardino G., Isacchi G., Testa U., Calabresi F. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose IL-2 bolus treatment. Cancer Res. 50:1990;5795-5800.
67. Hennemann B., Beckman G., Eichelmann A., Rehm A., Andreesen R. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon-γ and lipopolysaccharide. Cancer Immunol. Immunother. 45:1998;250-256.
68. Hennemann B., Rehm A., Kottke A., Meidenbauer N., Andreesen R. Adoptive immunotherapy with tumour cytotoxic macrophages derived from recombinant human granulocyte-macrophage colony-stimulating factor (rhuGM-CSF) mobilised peripheral blood monocytes. J. Immunother. 20:1997;365-371.